September 16, 2016
Histogenics Corporation (HSGX) proposes $30 M Private Placement
September 15, 2016
Capricor Therapeutics (CAPR) proposes public offering of 3 M shares at $3.20
September 15, 2016
Caladrius Biosciences (CLBS) $25M two tranche At-market-offering without warrants - SELL
September 7, 2016
BioLife Solutions (BLFS), cash getting tight?
August 30, 2016
OncoCyte Corporation (NYSEMKT: OCX) 3.24 M unit sale with 100% warrant coverage raises $10.5 M
August 23, 2016
Northwest Bio (NWBO) reprices warrants to raise cash
August 9, 2016
Fibrocell Science (FCSC) ditches share and warrant offering for $25 M convertible promissory notes and warrants
August 9, 2016
Immunocellular (NYSEMKT: IMUC) files 47 M shares offering at $0.16 with 32.25 M warrants to raise $7.4 M
August 8, 2016
Fibrocell Science (FCSC) files for an underwritten public offering.
August 8, 2016
Fate Therapeutics (FATE) 5.2 M shares offering to raise $10.3 M in private placement priced at $1.96
August 4, 2016
Cesca Therapeutics (KOOL) cashes in on upside move pricing $2.5 M Registered Direct Offering
July 11, 2016
ImmunoCellular Therapeutics (NYSEMKT: IMUC) proposes $24.2 M offering
July 5, 2016
Northwest Bio (NWBO) 7.4 M share offering at $0.50
June 16, 2016
BioTime (NYSEMKT: BTX) prices 7.322 M share offering - $2.39
June 14, 2016
Spark Therapeutics (ONCE) launches offering of 3.5 M shares
June 13, 2016
Cytori (CYTX) closes unit rights offering and bags $17.1 M
June 10, 2016
BioTime’s (NYSEMKT: BYX) Cell Cure subsidiary granted $2.2 M with obligation to repay
June 7, 2016
Cytori (CYTX) extends Rights Offering subscription to Friday, 6/10, adjusting Unit pricing
June 7, 2016
StemCells (STEM) Withdraws offering
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.